Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Biosimilars: initial excitement gives way to reality

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Global sales of biologic products.
Figure 2: Skills and barriers required to develop biosimilars.
Figure 3: Biosimilar suitability depends on drug class.

References

  1. Schellekens, H. How similar do 'biosimilars' need to be? Nature Biotechnol. 22, 1357–1359 (2004).

    Article  CAS  Google Scholar 

  2. Sheridan, C. First generic biologics finally approved. Nature Rev. Drug Discov. 5, 445 (2006).

    Article  CAS  Google Scholar 

  3. Dove, A. Betting on biogenerics. Nature Biotechnol. 19, 117–120 (2001).

    Article  Google Scholar 

  4. EMEA. Biotech medicines: first biosimilar drug on EU market. European Commission. Press release, [online] (2006).

  5. Sandoz, Inc. Sandoz gets precedent-setting US approval for Omnitrope® as first follow on version of a previously approved recombinant biotechnology drug. Press release, [online] (2006).

  6. EMEA/CHMP. Guideline on Similar Biological Medicinal Products containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues, [online] (2005).

  7. EMEA/CHMP. Guideline on Similar Biological Medicinal Products containing Biotechnology-Derived Proteins as Active Substance: Quality Issues http://www.emea.eu.int/pdfs/human/biosimilar/4934805en.pdf (2005).

  8. Ben-Maimon, C. S. & Garnick, R. Biogenerics at the crossroads. Nature Biotechnol. 24, 268–268 (2006)

    Google Scholar 

  9. Griffiths, S. From the analyst's couch: Betting on biogenerics. Nature Rev. Drug Discov. 3, 197–198 (2004)

    Article  CAS  Google Scholar 

  10. Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nature Rev. Drug Discov. 1, 457–462 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joanna Chertkow.

Related links

Related links

FURTHER INFORMATION

European Medicines Evaluation Agency: Guidelines onbiosimilar medicinal products

Food and Drug Administration: Information on Omnitrope

Rights and permissions

Reprints and permissions

About this article

Cite this article

Belsey, M., Harris, L., Das, R. et al. Biosimilars: initial excitement gives way to reality. Nat Rev Drug Discov 5, 535–536 (2006). https://doi.org/10.1038/nrd2093

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2093

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing